机构：[1]Third Military Medical University, Chongqing/CN,[2]Daping Hospital of Third Military Medical University, Chongqing/CN,[3]Tianjin People’s Hospital, Tianjin/CN,[4]The First People’s Hospital of Yunnan, Kunming/CN,[5]The First People’s Hospital of Yunnan Province,Kunming/CN,云南省第一人民医院[6]Shanxi Provincial Cancer Hospital, Taiyuan/CN,[7]Shanxi Provincial People’s Hospital, Taiyuan/CN,[8]Shanghai Xuhui District Central Hospital, Shanghai/CN,[9]Second Affiliated Hospital, Zunyi Medical University, Zunyi/CN,[10]The Second Affiliated Hospital of Zunyi Medical University, Zunyi/CN,[11]Hospital of Panjiang Coal Power Group, Liupanshui City/CN,[12]No.980 Hospital of PLA, Shijiazhuang/CN,[13]Yuxi People Hospital, Yuxi/CN,[14]Honghe No.3 People Hospital, GeJiao/CN,[15]Lianyungan No.2 People Hospital, Jiangsu, Lianyungan/CN,[16]Chongqing University Three Gorges Hospital, Chongqing/CN
第一作者机构：[1]Third Military Medical University, Chongqing/CN,
推荐引用方式(GB/T 7714)：
Wang D.,Feng Y.,Wang H.,et al.Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2023,18(11):S618-S618.
APA：
Wang, D.,Feng, Y.,Wang, H.,Peng, H.,Zhang, W....&Ren, B..(2023).Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC.JOURNAL OF THORACIC ONCOLOGY,18,(11)
MLA：
Wang, D.,et al."Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC".JOURNAL OF THORACIC ONCOLOGY 18..11(2023):S618-S618
医学